Brand Identity – Altasciences’ Evolution
Developing a brand identity that fully expresses your company’s contributions is a process that involves understanding your position in the marketplace, establishing your unique selling proposition and associated messaging, developing memorable and impactful creative elements, and finally, implementing strategies to support your brand identity.
ISSUE NO. 8 — Bioanalytical Challenges Encountered when Developing ADA Assays
Following the approval in 1986 of Orthoclone OKT3, the first therapeutic monoclonal antibody product, a class of new protein-based therapeutic drugs was introduced and became the dominant product class within the biopharmaceutical market.
Today, several monoclonal antibodies have been approved for the treatment of a variety of diseases, ranging from those that target orphan disease indications with a small patient population, to those that target much larger patient populations and demographics, such as for oncology, asthma, and rheumatoid arthritis.
In Issue 8 of The Altascientist, we explore the role of anti-drug antibodies (ADAs) in therapeutic development, their impact on efficacy, and detection strategies, including:
- Challenges encountered in ADA assays
- Cell-based or non-cell-based assays to measure neutralization
- How Altasciences can help
November 2014
Grands Prix québecois de la qualité
October 2015
October 2015
Annual Canada Awards for Excellence